Prostate Cancer

cabozantinib (XL184) - a novel wide-spectrum tyrosine kinase inhibitor (TKI) - achieved dramatic results in patients with castration-resistant prostate cancer

Though taking multivitamins has been linked to potential health benefits, a new study has found that an excessive consumption of multivitamins may not be beneficial.

Researchers are calling for prostate cancer survivors to incorporate physical activity into their daily routine.

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.

The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.

According to the British Journal of Cancer, a new study by London's Institute of Cancer Research finds that finger length might be an indicator of prostate cancer risk.

The Prostate Cancer Clinical States model was first proposed by Scher and colleagues nearly 10 years ago.

Behavioral therapy reduced episodes of urinary incontinence following radical prostatectomy by 55% in a study of 208 men with incontinence persisting %u22651 year following prostatectomy.

Androgen-deprivation therapy (ADT) is a widely accepted treatment for men with advanced or metastatic prostate cancer.

The FDA approved the injectable drug Jevtana (cabazitaxel), a microtubule inhibitor, in combination with prednisone as a second-line therapy for men with advanced castrate-resistant prostate cancer

Data presented at the recent 35th European Society for Medical Oncology Congress in Milan, Italy, showed a significant survival advantage for men with advanced metastatic castration resistant prostate cancer (CRPC) who received abiraterone acetate compared with placebo.

University of California researchers reported that prostate cancer cells subjected to pomegranate juice did not metastasize as readily as untreated prostate cancer cells.

Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week

Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.

The treatment of hormone-refractory prostate cancer often represents a therapeutic challenge. As the most common malignancy in men and the second-leading cause of cancer death in the US, the number of patients requiring posthormonal therapy is increasing.

This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).

The first revision in 12 years, the new guidelines are based on a growing body of evidence-based research and emphasize communication with the patient regarding risk, treatment options, and potential outcomes.

Cell Genesys has announced that it has completed recruitment of more than 600 patients into VITAL-1, the first of two ongoing Phase III clinical trials of GVAX immunotherapy for prostate cancer.

Provenge becomes the first immunotherapy vaccine against cancer to win FDA approval

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.

A common treatment option for prostate cancer is radiation therapy, which is as effective in treating the disease as surgical removal of the prostate.